Zobrazeno 1 - 10
of 23
pro vyhledávání: '"N. Yu. Lashch"'
Autor:
N. Yu. Lashch
Publikováno v:
Медицинский совет, Vol 0, Iss 19, Pp 62-68 (2020)
Multiple sclerosis (MS) is a chronic demyelinating disease of young employable people. Demyelination develops as a result of the autoimmune mechanisms of the damage to nerve fibers, while the neurodegenerative changes in the brain matter begin from t
Externí odkaz:
https://doaj.org/article/1c61d3e2486b48429508aed3dda3a537
Autor:
N. Yu. Lashch
Publikováno v:
Медицинский совет, Vol 0, Iss 8, Pp 88-94 (2020)
Multiple sclerosis (MS) is a chronic autoimmune inflammatory demyelinating and neurodegenerative disease with a multifactorial etiology of development. MS in most cases has a wave-like course (periods of exacerbations and remissions), over time, the
Externí odkaz:
https://doaj.org/article/6e4e20f93a444a158ccb64e7c02e203f
Autor:
N. Yu. Lashch
Publikováno v:
Медицинский совет, Vol 0, Iss 2, Pp 69-75 (2020)
Multiple sclerosis (MS) ranks first for prevalence among diseases affecting the CNS white matter with 2.5 million cases estimated globally. InRussia, the number of cases is about 200 thousand. MS in most cases has a wavy course (periods of exacerbati
Externí odkaz:
https://doaj.org/article/8daba0403b5b4d5d8fba3f725b0bcdac
Publikováno v:
Неврология, нейропсихиатрия, психосоматика, Vol 11, Iss 1, Pp 59-65 (2019)
One of the promising areas in the pathogenetic treatment of multiple sclerosis (MS) is anti-B-cell therapy using ocrelizumab, an anti-CD20 monoclonal antibody. The drug is indicated for primary progressive MS (PPMS), secondary progressive MS (SPMS) a
Externí odkaz:
https://doaj.org/article/6d34ad13ab324927adfcddc8f5abfd48
Publikováno v:
Неврология, нейропсихиатрия, психосоматика, Vol 10, Iss 1, Pp 70-73 (2018)
The review presents the data characterizing the mechanism of action of anti-B-cell therapy for multiple sclerosis (MS) and the results of clinical trials of ocrelizumab, the first drug of this group, which has been approved for use in MS. Multicenter
Externí odkaz:
https://doaj.org/article/98d90177b6664c2b873515bd61666341
Autor:
N. Yu. Lashch, A. N. Boiko
Publikováno v:
Неврология, нейропсихиатрия, психосоматика, Vol 8, Iss 2, Pp 117-120 (2016)
Multiple sclerosis (MS) is a demyelinating disease of the CNS, which affects mainly young able-bodied people; in this connection the problem of MS treatment assumes particular relevance. The paper reviews the main GALA (Glatiramer Acetate Low-frequen
Externí odkaz:
https://doaj.org/article/11e6b1f73ad64d0e9163b42dac00f130
Autor:
N. Yu. Lashch, A. N. Boiko
Publikováno v:
Неврология, нейропсихиатрия, психосоматика, Vol 8, Iss 1, Pp 82-85 (2016)
Multiple sclerosis (MS)-related fatigue is encountered in 75–92% of patients and it is one of the key symptoms that affect quality of life. Physicians and patients' relatives frequently underestimate MS-related fatigue; the latter may occur at any
Externí odkaz:
https://doaj.org/article/c1acb2e3384f43eaa39f25a602ddd7f7
Autor:
L. A. Babenko, D V Sazonov, T. O. Simaniv, M N Zakharova, Yu. V. Trinitatsky, A. V. Yarmoschuk, Kotov Sv, A N Boyko, F. A. Khabirov, N. Yu. Lashch, T I Khaibullin
Publikováno v:
Russian neurological journal. :44-51
The article presents the results of safety fi ndings during international multicenter randomized double-blind, active and placebo-controlled, comparative phase 3 trial. 158 patients with relapsing-remitting multiple sclerosis were randomly assigned i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e1b2cf938e879b1886439797901fb6f
https://doi.org/10.30629/2658-7947-2019-24-4-44-51
https://doi.org/10.30629/2658-7947-2019-24-4-44-51
Publikováno v:
Nevrologiâ, Nejropsihiatriâ, Psihosomatika, Vol 11, Iss 1, Pp 59-65 (2019)
One of the promising areas in the pathogenetic treatment of multiple sclerosis (MS) is anti-B-cell therapy using ocrelizumab, an anti-CD20 monoclonal antibody. The drug is indicated for primary progressive MS (PPMS), secondary progressive MS (SPMS) a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0afd3309f505bdc204a29583aa0b515b
https://doi.org/10.14412/2074-2711-2019-1-59-65
https://doi.org/10.14412/2074-2711-2019-1-59-65
Publikováno v:
Nevrologiâ, Nejropsihiatriâ, Psihosomatika, Vol 10, Iss 1, Pp 70-73 (2018)
The review presents the data characterizing the mechanism of action of anti-B-cell therapy for multiple sclerosis (MS) and the results of clinical trials of ocrelizumab, the first drug of this group, which has been approved for use in MS. Multicenter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8096afeedeb4773fdc8aa1d099490a6c
https://doi.org/10.14412/2074-2711-2018-1-70-73
https://doi.org/10.14412/2074-2711-2018-1-70-73